Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Respiratory Microbiota | Research

Resveratrol alleviates DSS-induced IBD in mice by regulating the intestinal microbiota-macrophage-arginine metabolism axis

Authors: Xinwei Xu, Dickson Kofi Wiredu Ocansey, Bing Pei, Yaqin Zhang, Naijian Wang, Zengxu Wang, Fei Mao

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

Inflammatory bowel disease (IBD) is a global disease with a growing public health concern and is associated with a complex interplay of factors, including the microbiota and immune system. Resveratrol, a natural anti-inflammatory and antioxidant agent, is known to relieve IBD but the mechanism involved is largely unexplored.

Methods

This study examines the modulatory effect of resveratrol on intestinal immunity, microbiota, metabolites, and related functions and pathways in the BALB/c mice model of IBD. Mouse RAW264.7 macrophage cell line was used to further explore the involvement of the macrophage-arginine metabolism axis. The treatment outcome was assessed through qRT-PCR, western blot, immunofluorescence, immunohistochemistry, and fecal 16S rDNA sequencing and UHPLC/Q-TOF–MS.

Results

Results showed that resveratrol treatment significantly reduced disease activity index (DAI), retained mice weight, repaired colon and spleen tissues, upregulated IL-10 and the tight junction proteins Occludin and Claudin 1, and decreased pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Resveratrol reduced the number of dysregulated metabolites and improved the gut microbial community structure and diversity, including reversing changes in the phyla Bacteroidetes, Proteobacteria, and Firmicutes, increasing ‘beneficial’ genera, and decreasing potential pathogens such as Lachnoclostridium, Acinobacter, and Serratia. Arginine–proline metabolism was significantly different between the colitis-treated and untreated groups. In the colon mucosa and RAW264.7 macrophage, resveratrol regulated arginine metabolism towards colon protection by increasing Arg1 and Slc6a8 and decreasing iNOS.

Conclusion

This uncovers a previously unknown mechanism of resveratrol treatment in IBD and provides the microbiota-macrophage-arginine metabolism axis as a potential therapeutic target for intestinal inflammation.

Available only for authorised users

Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56–66. https://doi.org/10.1038/s41575-020-00360-x.CrossRefPubMed

Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15(1):39–49. https://doi.org/10.1038/nrgastro.2017.136.CrossRefPubMed

Ocansey DKW, Zhang L, Wang Y, et al. Exosome-mediated effects and applications in inflammatory bowel disease. Biol Rev Camb Philos Soc. 2020;95(5):1287–307. https://doi.org/10.1111/brv.12608.CrossRefPubMedPubMedCentral

Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14(10):573–84. https://doi.org/10.1038/nrgastro.2017.88.CrossRefPubMedPubMedCentral

Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol. 2019;16(9):531–43. https://doi.org/10.1038/s41575-019-0172-4.CrossRefPubMed

Du Y, Rong L, Cong Y, et al. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease. Expert Opin Ther Targets. 2021;25(3):191–209. https://doi.org/10.1080/14728222.2021.1901079.CrossRefPubMed

Zhou X, Li W, Wang S, et al. YAP aggravates inflammatory bowel disease by regulating M1/M2 macrophage polarization and gut microbial homeostasis. Cell Rep. 2019;27(4):1176-1189.e5. https://doi.org/10.1016/j.celrep.2019.03.028.CrossRefPubMed

Ai L, Ren Y, Zhu M, et al. Synbindin restrains proinflammatory macrophage activation against microbiota and mucosal inflammation during colitis. Gut. 2021;70(12):2261–72. https://doi.org/10.1136/gutjnl-2020-321094.CrossRefPubMed

Leonardi I, Li X, Iliev ID. Macrophage interactions with fungi and bacteria in inflammatory bowel disease. Curr Opin Gastroenterol. 2018;34(6):392–7. https://doi.org/10.1097/mog.0000000000000479.CrossRefPubMedPubMedCentral

10.

Kieler M, Hofmann M, Schabbauer G. More than just protein building blocks: how amino acids and related metabolic pathways fuel macrophage polarization. FEBS J. 2021;288(12):3694–714. https://doi.org/10.1111/febs.15715.CrossRefPubMedPubMedCentral

11.

Ji L, Zhao X, Zhang B, et al. Slc6a8-mediated creatine uptake and accumulation reprogram macrophage polarization via regulating cytokine responses. Immunity. 2019;51(2):272-284.e7. https://doi.org/10.1016/j.immuni.2019.06.007.CrossRefPubMed

12.

Meng T, Xiao D, Muhammed A, et al. Anti-inflammatory action and mechanisms of resveratrol. Molecules. 2021. https://doi.org/10.3390/molecules26010229.CrossRefPubMedPubMedCentral

13.

Malaguarnera L. Influence of resveratrol on the immune response. Nutrients. 2019. https://doi.org/10.3390/nu11050946.CrossRefPubMedPubMedCentral

14.

Zhu F, Zheng J, Xu F, et al. Resveratrol alleviates dextran sulfate sodium-induced acute ulcerative colitis in mice by mediating PI3K/Akt/VEGFA pathway. Front Pharmacol. 2021;12:693982. https://doi.org/10.3389/fphar.2021.693982.CrossRefPubMedPubMedCentral

15.

Wang J, Zhang Z, Fang A, et al. Resveratrol attenuates inflammatory bowel disease in mice by regulating SUMO1. Biol Pharm Bull. 2020;43(3):450–7. https://doi.org/10.1248/bpb.b19-00786.CrossRefPubMed

16.

Wellington VNA, Sundaram VL, Singh S, Sundaram U. Dietary supplementation with vitamin d, fish oil or resveratrol modulates the gut microbiome in inflammatory bowel disease. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms23010206.CrossRefPubMedPubMedCentral

17.

Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–80. https://doi.org/10.1038/nature09944.CrossRefPubMedPubMedCentral

18.

Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2019;16(6):331–45. https://doi.org/10.1038/s41575-019-0121-2.CrossRefPubMed

19.

Zhang W, Zou G, Li B, et al. Fecal microbiota transplantation (FMT) alleviates experimental colitis in mice by gut microbiota regulation. J Microbiol Biotechnol. 2020;30(8):1132–41. https://doi.org/10.4014/jmb.2002.02044.CrossRefPubMedPubMedCentral

20.

Wang CS, Li WB, Wang HY, et al. VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice. World J Gastroenterol. 2018;24(37):4254–62. https://doi.org/10.3748/wjg.v24.i37.4254.CrossRefPubMedPubMedCentral

21.

Liang JQ, Li T, Nakatsu G, et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut. 2020;69(7):1248–57. https://doi.org/10.1136/gutjnl-2019-318532.CrossRefPubMed

22.

Tang MS, Poles J, Leung JM, et al. Inferred metagenomic comparison of mucosal and fecal microbiota from individuals undergoing routine screening colonoscopy reveals similar differences observed during active inflammation. Gut Microbes. 2015;6(1):48–56. https://doi.org/10.1080/19490976.2014.1000080.CrossRefPubMedPubMedCentral

23.

Gupta V, Sharma S, Pal K, et al. Serratia, no longer an uncommon opportunistic pathogen—case series & review of literature. Infect Disord Drug Targets. 2021;21(7):e300821191666. https://doi.org/10.2174/1871526521666210222125215.CrossRefPubMed

24.

Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223–37. https://doi.org/10.1038/s41575-019-0258-z.CrossRefPubMed

25.

Gasaly N, de Vos P, Hermoso MA. Impact of bacterial metabolites on gut barrier function and host immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol. 2021;12:658354. https://doi.org/10.3389/fimmu.2021.658354.CrossRefPubMedPubMedCentral

26.

Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021;70(6):1174–82. https://doi.org/10.1136/gutjnl-2020-323071.CrossRefPubMed

27.

Xu X, Ocansey DKW, Hang S, et al. The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease. Gut Pathog. 2022;14(1):26. https://doi.org/10.1186/s13099-022-00499-9.CrossRefPubMedPubMedCentral

28.

Ocansey DKW, Zhang Z, Xu X, et al. Mesenchymal stem cell-derived exosome mitigates colitis via the modulation of the gut metagenomics-metabolomics-farnesoid X receptor axis. Biomater Sci. 2022;10(17):4822–36. https://doi.org/10.1039/d2bm00559j.CrossRefPubMed

29.

Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front Immunol. 2019;10:1084. https://doi.org/10.3389/fimmu.2019.01084.CrossRefPubMedPubMedCentral

30.

Nunes S, Danesi F, Del Rio D, Silva P. Resveratrol and inflammatory bowel disease: the evidence so far. Nutr Res Rev. 2018;31(1):85–97. https://doi.org/10.1017/s095442241700021x.CrossRefPubMed

31.

Hou CY, Tain YL, Yu HR, Huang LT. The effects of resveratrol in the treatment of metabolic syndrome. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20030535.CrossRefPubMedPubMedCentral

32.

Zhou DD, Luo M, Huang SY, et al. Effects and mechanisms of resveratrol on aging and age-related diseases. Oxid Med Cell Longev. 2021;2021:9932218. https://doi.org/10.1155/2021/9932218.CrossRefPubMedPubMedCentral

33.

Pignet AL, Schellnegger M, Hecker A, et al. Resveratrol-induced signal transduction in wound healing. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms222312614.CrossRefPubMedPubMedCentral

34.

Breuss JM, Atanasov AG, Uhrin P. Resveratrol and its effects on the vascular system. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20071523.CrossRefPubMedPubMedCentral

35.

Vervandier-Fasseur D, Latruffe N. The potential use of resveratrol for cancer prevention. Molecules. 2019. https://doi.org/10.3390/molecules24244506.CrossRefPubMedPubMedCentral

36.

Samsami-Kor M, Daryani NE, Asl PR, Hekmatdoost A. Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-blind, Placebo-controlled. Pilot Study Arch Med Res. 2015;46(4):280–5. https://doi.org/10.1016/j.arcmed.2015.05.005.CrossRefPubMed

37.

Abdallah DM, Ismael NR. Resveratrol abrogates adhesion molecules and protects against TNBS-induced ulcerative colitis in rats. Can J Physiol Pharmacol. 2011;89(11):811–8. https://doi.org/10.1139/y11-080.CrossRefPubMed

38.

Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019;76(3):473–93. https://doi.org/10.1007/s00018-018-2943-4.CrossRefPubMed

39.

Vandeputte D, Falony G, Vieira-Silva S, et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65(1):57–62. https://doi.org/10.1136/gutjnl-2015-309618.CrossRefPubMed

40.

Koliada A, Syzenko G, Moseiko V, et al. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol. 2017;17(1):120. https://doi.org/10.1186/s12866-017-1027-1.CrossRefPubMedPubMedCentral

41.

Li F, Han Y, Cai X, et al. Dietary resveratrol attenuated colitis and modulated gut microbiota in dextran sulfate sodium-treated mice. Food Funct. 2020;11(1):1063–73. https://doi.org/10.1039/c9fo01519a.CrossRefPubMedPubMedCentral

42.

Alrafas HR, Busbee PB, Nagarkatti M, Nagarkatti PS. Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells. J Leukoc Biol. 2019;106(2):467–80. https://doi.org/10.1002/jlb.3a1218-476rr.CrossRefPubMed

43.

Wang P, Li D, Ke W, et al. Resveratrol-induced gut microbiota reduces obesity in high-fat diet-fed mice. Int J Obes (Lond). 2020;44(1):213–25. https://doi.org/10.1038/s41366-019-0332-1.CrossRefPubMed

44.

Cai TT, Ye XL, Li RR, et al. Resveratrol modulates the gut microbiota and inflammation to protect against diabetic nephropathy in mice. Front Pharmacol. 2020;11:1249. https://doi.org/10.3389/fphar.2020.01249.CrossRefPubMedPubMedCentral

45.

Chen ML, Yi L, Zhang Y, et al. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. MBio. 2016;7(2):e02210-e2215. https://doi.org/10.1128/mBio.02210-15.CrossRefPubMedPubMedCentral

46.

Yao M, Fei Y, Zhang S, et al. Gut microbiota composition in relation to the metabolism of oral administrated resveratrol. Nutrients. 2022. https://doi.org/10.3390/nu14051013.CrossRefPubMedPubMedCentral

47.

Li JY, Guo YC, Zhou HF, et al. Arginine metabolism regulates the pathogenesis of inflammatory bowel disease. Nutr Rev. 2022. https://doi.org/10.1093/nutrit/nuac070.CrossRefPubMedPubMedCentral

48.

Hall CHT, Lee JS, Murphy EM, et al. Creatine transporter, reduced in colon tissues from patients with inflammatory bowel diseases, regulates energy balance in intestinal epithelial cells, epithelial integrity, and barrier function. Gastroenterology. 2020;159(3):984-998.e1. https://doi.org/10.1053/j.gastro.2020.05.033.CrossRefPubMed

49.

Borren NZ, Plichta D, Joshi AD, et al. Multi-"-Omics" profiling in patients with quiescent inflammatory bowel disease identifies biomarkers predicting relapse. Inflamm Bowel Dis. 2020;26(10):1524–32. https://doi.org/10.1093/ibd/izaa183.CrossRefPubMedPubMedCentral

50.

Mindikoglu AL, Opekun AR, Putluri N, et al. Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Transl Res. 2018;195:25–47. https://doi.org/10.1016/j.trsl.2017.12.002.CrossRefPubMed

Title: Resveratrol alleviates DSS-induced IBD in mice by regulating the intestinal microbiota-macrophage-arginine metabolism axis
Authors: Xinwei Xu
Dickson Kofi Wiredu Ocansey
Bing Pei
Yaqin Zhang
Naijian Wang
Zengxu Wang
Fei Mao
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Respiratory Microbiota
Chronic Inflammatory Bowel Disease
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01257-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Resveratrol alleviates DSS-induced IBD in mice by regulating the intestinal microbiota-macrophage-arginine metabolism axis

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Adhatoda vasica and Tinospora cordifolia extracts ameliorate clinical and molecular markers in mild COVID-19 patients: a randomized open-label three-armed study

Declined plasma microfibrillar-associated protein 4 levels in acute coronary syndrome

A nomogram for predicting the risk of new vertebral compression fracture after percutaneous kyphoplasty

Clinical outcomes in COVID-19 among patients with hypertension in the Philippine CORONA Study

Cuproptosis-Related Ferroptosis genes for Predicting Prognosis in kidney renal clear cell carcinoma

FVC/DLCO identifies pulmonary hypertension and predicts 5-year all-cause mortality in patients with COPD